两性霉素B、卡泊芬净、氟康唑和伏立康唑对血液系统恶性肿瘤患者罕见念珠菌属血流分离株的体外药效学特征
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
作者信息
Di Bonaventura Giovanni, Spedicato Ilaria, Picciani Carla, D'Antonio Domenico, Piccolomini Raffaele
机构信息
Center of Excellence on Aging, Room 27, 5th level, "G. D'Annunzio" University, Via Colle dell'Ara, 66100 Chieti, Italy.
出版信息
Antimicrob Agents Chemother. 2004 Nov;48(11):4453-6. doi: 10.1128/AAC.48.11.4453-4456.2004.
Abstract
Time-kill and postantifungal effect (PAFE) of amphotericin B, caspofungin, fluconazole, and voriconazole were determined against clinical isolates of Candida guilliermondii, Candida kefyr, and Candida lusitaniae. Azoles displayed fungistatic activity and no measurable PAFE, regardless of the concentration tested. Amphotericin B and caspofungin demonstrated concentration-dependent fungicidal activity, although amphotericin B only produced a significant dose-dependent PAFE against all isolates tested.
摘要
测定了两性霉素B、卡泊芬净、氟康唑和伏立康唑对季也蒙念珠菌、克菲念珠菌和葡萄牙念珠菌临床分离株的时间杀菌和抗真菌后效应（PAFE）。无论测试浓度如何，唑类均表现出抑菌活性且无可测量的PAFE。两性霉素B和卡泊芬净表现出浓度依赖性杀菌活性，尽管两性霉素B仅对所有测试分离株产生显著的剂量依赖性PAFE。
相似文献
1
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Antimicrob Agents Chemother. 2004 Nov;48(11):4453-6. doi: 10.1128/AAC.48.11.4453-4456.2004.
2
Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
Med Mycol. 2013 Jan;51(1):60-5. doi: 10.3109/13693786.2012.697198. Epub 2012 Jul 2.
3
In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
J Infect Chemother. 2009 Feb;15(1):1-5. doi: 10.1007/s10156-008-0653-9. Epub 2009 Mar 12.
4
Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.
Mycopathologia. 2012 Jan;173(1):27-34. doi: 10.1007/s11046-011-9459-x. Epub 2011 Aug 13.
5
In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Med Mycol. 2005 Mar;43(2):171-8. doi: 10.1080/13693780410001731565.
6
7
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
J Clin Microbiol. 1999 Mar;37(3):870-2. doi: 10.1128/JCM.37.3.870-872.1999.
8
The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mem Inst Oswaldo Cruz. 2012 May;107(3):433-6. doi: 10.1590/s0074-02762012000300022.
9
National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
J Antimicrob Chemother. 2004 Feb;53(2):283-9. doi: 10.1093/jac/dkh053. Epub 2003 Dec 19.
10
Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.
Ann Lab Med. 2012 Nov;32(6):426-8. doi: 10.3343/alm.2012.32.6.426. Epub 2012 Oct 17.
引用本文的文献
1
Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against species in an pharmacokinetic/pharmacodynamic model.
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022524. doi: 10.1128/aac.00225-24. Epub 2024 Jul 3.
2
Caregiver skin infection causing peritoneal dialysis-associated peritonitis.
Med Mycol Case Rep. 2024 May 25;44:100653. doi: 10.1016/j.mmcr.2024.100653. eCollection 2024 Jun.
3
In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in spp.
J Fungi (Basel). 2023 Dec 12;9(12):1188. doi: 10.3390/jof9121188.
4
Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris: Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model.
J Infect Dis. 2024 Feb 14;229(2):599-607. doi: 10.1093/infdis/jiad583.
5
Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.
Crit Care. 2023 Nov 20;27(1):449. doi: 10.1186/s13054-023-04742-w.
6
Postantifungal Effect of Antifungal Drugs against : What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?
J Fungi (Basel). 2022 Jul 12;8(7):727. doi: 10.3390/jof8070727.
7
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.
Intensive Care Med. 2019 Jun;45(6):789-805. doi: 10.1007/s00134-019-05599-w. Epub 2019 Mar 25.
8
Synthesis, characterization, and in vitro activity against spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid).
Nanotechnol Sci Appl. 2017 May 16;10:95-104. doi: 10.2147/NSA.S96018. eCollection 2017.
9
Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates.
Braz J Microbiol. 2009 Jan;40(1):163-9. doi: 10.1590/S1517-838220090001000028. Epub 2009 Mar 1.
10
Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
Antimicrob Agents Chemother. 2013 Oct;57(10):4841-7. doi: 10.1128/AAC.00850-13. Epub 2013 Jul 22.
本文引用的文献
1
In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
Diagn Microbiol Infect Dis. 2004 Feb;48(2):101-5. doi: 10.1016/j.diagmicrobio.2003.09.009.
2
Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
J Antimicrob Chemother. 2004 Mar;53(3):526-9. doi: 10.1093/jac/dkh106. Epub 2004 Feb 12.
3
Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.
J Clin Microbiol. 2004 Feb;42(2):718-21. doi: 10.1128/JCM.42.2.718-721.2004.
4
Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):33-7. doi: 10.1016/j.diagmicrobio.2003.08.002.
5
Caspofungin activity against clinical isolates of fluconazole-resistant Candida.
J Clin Microbiol. 2003 Dec;41(12):5729-31. doi: 10.1128/JCM.41.12.5729-5731.2003.
6
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.
Antimicrob Agents Chemother. 2003 Oct;47(10):3149-54. doi: 10.1128/AAC.47.10.3149-3154.2003.
7
Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
J Clin Microbiol. 2003 Mar;41(3):1087-90. doi: 10.1128/JCM.41.3.1087-1090.2003.
8
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Antimicrob Agents Chemother. 2003 Mar;47(3):1068-71. doi: 10.1128/AAC.47.3.1068-1071.2003.
9
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
J Clin Microbiol. 2003 Jan;41(1):78-83. doi: 10.1128/JCM.41.1.78-83.2003.
10
New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve.
Antimicrob Agents Chemother. 2002 Dec;46(12):4016-8. doi: 10.1128/AAC.46.12.4016-4018.2002.
Zotero 插件